ACE2 and COVID-19: The human keratin 18 promoter directs human ACE2 expression to epithelia, specifically the airway epithelia, where the viral infection typically begins, making K18-hACE2 susceptible to SARS-CoV-2, therefore useful for studying antiviral therapies against COVID-19 [3,13,14,15,16,17,18,19].